The global veterinary pharmacovigilance market size accounted for USD 986.84 million in 2024, grew to USD 1,109.21 million in 2025 and is projected to surpass around USD 3,176.21 million by 2034, representing a healthy CAGR of 12.40% between 2024 and 2034. The North America veterinary pharmacovigilance market size is worth around USD 414.47 million in 2024 and is expected to grow at a fastest CAGR of 12.53% during the forecast period.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Veterinary Pharmacovigilance Market
5.1. COVID-19 Landscape: Veterinary Pharmacovigilance Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Veterinary Pharmacovigilance Market, By Solution
8.1. Veterinary Pharmacovigilance Market Revenue and Volume Forecast, by Solution, 2024-2034
8.1.1. Software
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Services
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 9. Global Veterinary Pharmacovigilance Market, By Product
9.1. Veterinary Pharmacovigilance Market Revenue and Volume Forecast, By Product, 2024-2034
9.1.1. Biologics
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Anti-infectives
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Others
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 10. Global Veterinary Pharmacovigilance Market, By Type
10.1. Veterinary Pharmacovigilance Market Revenue and Volume Forecast, by Type, 2024-2034
10.1.1. In-house
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. Contract Outsourcing
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 11. Global Veterinary Pharmacovigilance Market, By Animal Type
11.1. Veterinary Pharmacovigilance Market Revenue and Volume Forecast, by Animal Type, 2024-2034
11.1.1. Dogs
11.1.1.1. Market Revenue and Volume Forecast (2021-2034)
11.1.2. Cats
11.1.2.1. Market Revenue and Volume Forecast (2021-2034)
11.1.3. Others
11.1.3.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 12. Global Veterinary Pharmacovigilance Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.1.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.1.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.1.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.1.5.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.1.5.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.1.5.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.1.6.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.1.6.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.1.6.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.2.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.2.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.2.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.2.5.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.2.5.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.2.5.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.2.6.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.2.6.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.2.6.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.2.7.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.2.7.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.2.7.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.2.8.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.2.8.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.2.8.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.3.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.3.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.3.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.3.5.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.3.5.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.3.5.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.3.6.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.3.6.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.3.6.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.3.7.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.3.7.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.3.7.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.3.8.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.3.8.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.3.8.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.4.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.4.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.4.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.4.5.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.4.5.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.4.5.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.4.6.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.4.6.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.4.6.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.4.7.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.4.7.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.4.7.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.4.8.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.4.8.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.4.8.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.5.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.5.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.5.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.5.5.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.5.5.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.5.5.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Solution (2021-2034)
12.5.6.2. Market Revenue and Volume Forecast, By Product (2021-2034)
12.5.6.3. Market Revenue and Volume Forecast, by Type (2021-2034)
12.5.6.4. Market Revenue and Volume Forecast, by Animal Type (2021-2034)
Chapter 13. Company Profiles
13.1. Zoetis Inc.
13.1.1. Company Overview
13.1.2. Type Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Merck & Co., Inc. (Merck Animal Health)
13.2.1. Company Overview
13.2.2. Type Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Boehringer Ingelheim Animal Health
13.3.1. Company Overview
13.3.2. Type Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Elanco Animal Health
13.4.1. Company Overview
13.4.2. Type Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Virbac
13.5.1. Company Overview
13.5.2. Type Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Bayer Animal Health
13.6.1. Company Overview
13.6.2. Type Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Ceva Santé Animale
13.7.1. Company Overview
13.7.2. Type Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Vetoquinol
13.8.1. Company Overview
13.8.2. Type Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. IDEXX Laboratories, Inc.
13.9.1. Company Overview
13.9.2. Type Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Covetrus
13.10.1. Company Overview
13.10.2. Type Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample